Revenue generated by Qiagen for the second quarter could reach $454.1 million, preliminary results show. Net sales are expected to be 18% to 19% higher than the same period in 2019 due to demand for COVID-19 testing products.
Andrew Davis has been appointed chief commercial officer at Silk Road Medical. Davis previously served as VP of advanced wound therapy sales and marketing for the US and Canada at Acelity.
The Steripath Gen2 Initial Specimen Diversion Device with an integrated syringe, used to reduce blood culture contamination, has been released by Magnolia Medical.
White House Chief of Staff Mark Meadows said President Donald Trump will be signing three executive orders that will significantly lower prescription drug prices. Meadows did not specify the content or timing of the executive orders.
A judge with the US International Trade Commission has preliminarily ruled in favor of AbbVie's Allergan unit and its South Korean partner Medytox, which seek to block imports of Jeuveau, a Botox rival from Evolus and South Korean firm Daewoong Pharmaceutical. A full commission ruling is expected in November.
The Department of Agriculture's Food Safety and Inspection Service denied a petition from the Physicians Committee for Responsible Medicine to require all meat and poultry establishments to conduct weekly COVID-19 testing on workers and require meat and poultry product labeling to carry a warning that "this product has not been certified virus-free." In a letter sent to the group, FSIS said they "have determined that neither the petition nor the addendum includes scientific studies or other information to demonstrate that COVID-19 can be transmitted to humans by meat or poultry products."
Foghorn Therapeutics and Merck have signed a deal worth as much as $425 million that aims to target DNA shape to develop a cancer treatment. "I think this biology has been unexplored and unexploited as drug, and I think the time is right," said Foghorn CEO Adrian Gottschalk.